Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 446

1.
2.

Anti-OX40 stimulation in vivo enhances CD8+ memory T cell survival and significantly increases recall responses.

Ruby CE, Redmond WL, Haley D, Weinberg AD.

Eur J Immunol. 2007 Jan;37(1):157-66.

3.

During viral infection of the respiratory tract, CD27, 4-1BB, and OX40 collectively determine formation of CD8+ memory T cells and their capacity for secondary expansion.

Hendriks J, Xiao Y, Rossen JW, van der Sluijs KF, Sugamura K, Ishii N, Borst J.

J Immunol. 2005 Aug 1;175(3):1665-76.

4.

Functional dichotomy between OX40 and 4-1BB in modulating effector CD8 T cell responses.

Lee SW, Park Y, Song A, Cheroutre H, Kwon BS, Croft M.

J Immunol. 2006 Oct 1;177(7):4464-72.

5.

OX40 and Bcl-xL promote the persistence of CD8 T cells to recall tumor-associated antigen.

Song A, Tang X, Harms KM, Croft M.

J Immunol. 2005 Sep 15;175(6):3534-41.

6.

4-1BB and OX40 act independently to facilitate robust CD8 and CD4 recall responses.

Dawicki W, Bertram EM, Sharpe AH, Watts TH.

J Immunol. 2004 Nov 15;173(10):5944-51.

7.

Ligation of the OX40 co-stimulatory receptor reverses self-Ag and tumor-induced CD8 T-cell anergy in vivo.

Redmond WL, Gough MJ, Weinberg AD.

Eur J Immunol. 2009 Aug;39(8):2184-94. doi: 10.1002/eji.200939348.

8.

Costimulation of CD8 T cell responses by OX40.

Bansal-Pakala P, Halteman BS, Cheng MH, Croft M.

J Immunol. 2004 Apr 15;172(8):4821-5.

9.

IL-12 is required for anti-OX40-mediated CD4 T cell survival.

Ruby CE, Montler R, Zheng R, Shu S, Weinberg AD.

J Immunol. 2008 Feb 15;180(4):2140-8.

10.

4-1BB and OX40 stimulation enhance CD8 and CD4 T-cell responses to a DNA prime, poxvirus boost vaccine.

Munks MW, Mourich DV, Mittler RS, Weinberg AD, Hill AB.

Immunology. 2004 Aug;112(4):559-66.

11.
12.

Danger and OX40 receptor signaling synergize to enhance memory T cell survival by inhibiting peripheral deletion.

Maxwell JR, Weinberg A, Prell RA, Vella AT.

J Immunol. 2000 Jan 1;164(1):107-12.

13.
14.

Expression and costimulatory effects of the TNF receptor superfamily members CD134 (OX40) and CD137 (4-1BB), and their role in the generation of anti-tumor immune responses.

Taraban VY, Rowley TF, O'Brien L, Chan HT, Haswell LE, Green MH, Tutt AL, Glennie MJ, Al-Shamkhani A.

Eur J Immunol. 2002 Dec;32(12):3617-27.

15.

OX40 agonist therapy enhances CD8 infiltration and decreases immune suppression in the tumor.

Gough MJ, Ruby CE, Redmond WL, Dhungel B, Brown A, Weinberg AD.

Cancer Res. 2008 Jul 1;68(13):5206-15. doi: 10.1158/0008-5472.CAN-07-6484.

16.

STAT5-mediated signals sustain a TCR-initiated gene expression program toward differentiation of CD8 T cell effectors.

Verdeil G, Puthier D, Nguyen C, Schmitt-Verhulst AM, Auphan-Anezin N.

J Immunol. 2006 Apr 15;176(8):4834-42.

17.

Cooperation between CD4 and CD8 T cells for anti-tumor activity is enhanced by OX40 signals.

Song A, Song J, Tang X, Croft M.

Eur J Immunol. 2007 May;37(5):1224-32.

18.

The OX40 costimulatory receptor determines the development of CD4 memory by regulating primary clonal expansion.

Gramaglia I, Jember A, Pippig SD, Weinberg AD, Killeen N, Croft M.

J Immunol. 2000 Sep 15;165(6):3043-50.

20.

OX40-mediated differentiation to effector function requires IL-2 receptor signaling but not CD28, CD40, IL-12Rbeta2, or T-bet.

Williams CA, Murray SE, Weinberg AD, Parker DC.

J Immunol. 2007 Jun 15;178(12):7694-702.

Supplemental Content

Support Center